Kazuhiro Hatta

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Hideaki Tsuji, Ran Nakashima, Yuji Hosono et al. · Arthritis & Rheumatology · 2019 · 344 citations · Full text

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

The prognostic value of HRCT in myositis-associated interstitial lung disease

Kiminobu Tanizawa, Tomohiro Handa, Ran Nakashima et al. · Respiratory Medicine · 2013 · 117 citations · Full text

Inflammatory Lung Disease, Autoimmune Disease, Advanced Lung Disease +6

Clinical and Radiological Features of Acute-Onset Diffuse Interstitial Lung Diseases in Patients with Rheumatoid Arthritis Receiving Treatment with Biological Agents: Importance of <i>Pneumocystis</i> Pneumonia in Japan Revealed by a Multicenter Study

Hideto Kameda, Hitoshi Tokuda, Fumikazu Sakai et al. · Internal Medicine · 2011 · 77 citations · Full text